Repeal of Michigan’s Engler-era drug immunity law passes House - Michigan Advance
Michigan House passes repeal of Engler-era drug immunity law, potentially exposing pharmaceutical manufacturers to state liability for drug-related harms.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 28, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. All pharmaceutical manufacturers operating in or distributing to Michigan, including branded, generic, API, contract manufacturers, and compounding outsourcers. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Monitor legislative progress; if passed by Senate and signed by governor, effective immediately upon enactment.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
Repeal of Michigan's drug immunity law removes a key legal shield that protected manufacturers from certain state tort claims, increasing litigation risk.
Who it affects
All pharmaceutical manufacturers operating in or distributing to Michigan, including branded, generic, API, contract manufacturers, and compounding outsourcers.
What you must do
Review product liability insurance coverage and assess exposure to Michigan state court lawsuits; consult legal counsel on potential changes to risk management.
Deadline
Monitor legislative progress; if passed by Senate and signed by governor, effective immediately upon enactment.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- Court of Appeals Affirms Judgment that Struck Down Rule Mandating Price Disclosure in Pharmaceutical Ads - Holland & Knight
- Virginia Prepares to Accept Applications for a Single Medical Cannabis License for Health Service Area 1, Which Includes the Shenandoah Valley - Foley Hoag
- Glenmark suffers recall, warning letter after subpar investigation into tablet manufacturing glitch - Fierce Pharma
- February 17, 2026: Pennsylvania compounding pharmacy earns another FDA warning letter - Partnership for Safe Medicines
- Governor signs bill requiring informed consent for nursing home patients for prescription of antipsychotic drugs - Oklahoma State Senate (.gov)